Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday
Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See how other analysts view these stocks.
Stocks · News reference
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026
Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15
HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a Buy and lowers the price target from $18 to $15.
Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10